What type of study is this?

This is a In Vitro Study study.

What question did this study set out to answer?

The study aims to enhance the targeting of activated hepatic stellate cells using engineered exosomes to treat hepatic fibrosis.

February 11, 2026Open Access

Engineered exosomes from umbilical cord mesenchymal stem cells with pPB modification attenuate hepatic fibrosis via hepatic stellate cell targeting

Key Points

The study aims to enhance the targeting of activated hepatic stellate cells using engineered exosomes to treat hepatic fibrosis.
Developed hUCMSC-Exos@pPB exosomes for specific targeting of activated hepatic stellate cells.
Evaluated targeting efficiency using in vivo imaging and immunofluorescence techniques.
Assessed biosafety through CCK-8 assays and organ staining in animal models.
Analyzed liver function parameters and fibrogenic protein expression during treatment.
Conducted transcriptome RNA sequencing to explore underlying mechanisms.
HUCMSC-Exos@pPB effectively targeted activated hepatic stellate cells.
Demonstrated reduced hepatic fibrosis as indicated by histopathological evaluation.
Significantly improved liver function parameters, including reduced aspartate aminotransferase and alanine aminotransferase levels.
Identified the PI3K-Akt signaling pathway as a key mechanism for anti-fibrotic effects.

Abstract

Current therapeutic strategies for hepatic fibrosis remain limited, primarily due to lack of effectively targeting activated hepatic stellate cells (aHSCs) without compromising treatment safety. Although human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) exhibit promising therapeutic potential, their clinical application is constrained by rapid clearance via the mononuclear phagocyte system (MPS) and inadequate target specificity. This study aimed to develop engineered exosomes with enhanced targeting capabilities toward aHSCs through surface modification, thereby improving their anti-fibrotic efficacy. We developed an exosomal delivery system modified with a pPB cyclic peptide (hUCMSC-Exos@pPB) using DSPE-PEG-NH2-based nanoengineering to enable specific targeting of aHSCs. The targeting efficiency of hUCMSC-Exos@pPB was assessed via in vivo imaging and immunofluorescence co-localization analysis with α-smooth muscle actin (α-SMA). Biosafety of the hUCMSC-Exos@pPB delivery system was comprehensively evaluated through CCK-8 assays in vitro, hematoxylin and eosin (HE) staining of major organs in experimental animals, and the analysis of liver and kidney function indicators. The anti-liver fibrosis efficacy of hUCMSC-Exos@pPB was evaluated through multiple approaches, including histopathological assessments (HE, Masson, and Sirius red staining), oxidative stress markers (malondialdehyde and NADPH oxidase 4), measurement of liver function parameters (aspartate aminotransferase and alanine aminotransferase), and analysis of fibrogenic protein expression (α-SMA and COL1a1) in vivo and in HSC-T6 cells. Transcriptome RNA sequencing of liver tissue revealed the PI3K-Akt signaling pathway as a pivotal mechanism through which hUCMSC-Exos@pPB exerts its anti-fibrotic effects. Through rational surface engineering with pPB peptide ligands, we developed a novel exosomal nanoplatform that effectively evades clearance by the MPS and achieves targeted delivery to aHSCs. This strategy significantly enhanced the therapeutic efficacy of hUCMSC-Exos against hepatic fibrosis, therey providing a promising translational approach for the precision treatment of chronic liver diseases.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Wang et al. (Mon,) studied this question.

synapsesocial.com/papers/698be001058ab1890a13bae4 https://doi.org/https://doi.org/10.1186/s12967-025-07658-x

Bookmark

View Full Paper